Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer

NCT04521764 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04521764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04521764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
September 23, 2020
Completion date
August 15, 2027
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, invasive breast carcinoma, metastatic breast adenocarcinoma, recurrent breast carcinoma, stage iv breast cancer ajcc v6 and v7